Chicago-One of the first large studies to determine the 10-year efficacy of brachytherapy in men with prostate cancer shows that patients receiving a dose of at least 160 Gy have a 93% chance of being free of biochemical failure and a 95.4% chance of local control at 10 years.
Dr. Schuster highlights the FDA approval of imaging agent flotufolastat F 18 in prostate cancer
June 22nd 2023"We're excited that the FDA approval of this radiotracer gives us yet more tools at our disposal to diagnose prostate cancer in all its forms, from early to late in the disease process," says David M. Schuster, MD, FACR.